S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What To Do With Your Trades Today (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What To Do With Your Trades Today (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What To Do With Your Trades Today (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What To Do With Your Trades Today (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What To Do With Your Trades Today (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What To Do With Your Trades Today (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What To Do With Your Trades Today (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What To Do With Your Trades Today (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:TMDX

TransMedics Group - TMDX Stock Forecast, Price & News

$75.73
+1.96 (+2.66%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$74.05
$78.90
50-Day Range
$61.97
$82.33
52-Week Range
$20.36
$83.48
Volume
544,517 shs
Average Volume
426,215 shs
Market Capitalization
$2.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.57

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
5.5% Downside
$71.57 Price Target
Short Interest
Bearish
5.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$12.51 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.89) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

806th out of 1,004 stocks

Electromedical Equipment Industry

17th out of 24 stocks


TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
TMDX TransMedics Group, Inc.
TMDX.OQ - | Stock Price & Latest News | Reuters
TransMedics Group Reaches Analyst Target Price
My Top Pick For 2023: TransMedics Group
TransMedics Remains A Buy Heading Into Q3 Earnings
5 Analysts Have This to Say About TransMedics Group
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
2/22/2023
Today
4/01/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.57
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
-5.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-36,230,000.00
Pretax Margin
-38.70%

Debt

Sales & Book Value

Annual Sales
$93.46 million
Book Value
$5.87 per share

Miscellaneous

Free Float
29,395,000
Market Cap
$2.44 billion
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Waleed H. HassaneinWaleed H. Hassanein
    President, Chief Executive Officer & Director
  • John F. CareyJohn F. Carey
    Vice President-Operations
  • Stephen GordonStephen Gordon
    Chief Financial Officer, Secretary & Treasurer
  • Mark Anderson
    Senior Director-Technology Development
  • Phillip Camp
    Chief Medical Officer













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

7 Wall Street analysts have issued 12 month price targets for TransMedics Group's shares. Their TMDX share price forecasts range from $45.00 to $85.00. On average, they expect the company's stock price to reach $71.57 in the next twelve months. This suggests that the stock has a possible downside of 5.5%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2023?

TransMedics Group's stock was trading at $61.72 on January 1st, 2023. Since then, TMDX stock has increased by 22.7% and is now trading at $75.73.
View the best growth stocks for 2023 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings results on Wednesday, February, 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. The company earned $31.38 million during the quarter, compared to analysts' expectations of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative trailing twelve-month return on equity of 29.82%. TransMedics Group's quarterly revenue was up 224.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) earnings per share.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $134.71 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $75.73.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.44 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 4/1/2023 by MarketBeat.com Staff